Article info
Section 1: Introductory statements and governance
1ISG-022 Economic analysis after the incorporation of bevacizumab biosimilar in a third level hospital
Citation
1ISG-022 Economic analysis after the incorporation of bevacizumab biosimilar in a third level hospital
Publication history
- First published March 14, 2021.
Online issue publication
March 15, 2021
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.